openPR Logo
Press release

Diabetic Kidney Disease Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment By DelveInsight | Orbsen Therapeutics, Dimerix Bioscience, Inversago Pharma, CSL Behring, Kyowa kirin

03-18-2025 08:37 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Diabetic Kidney Disease Pipeline 2025: MOA, ROA, FDA-Approved

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Kidney Disease pipeline constitutes key companies continuously working towards developing Diabetic Kidney Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Diabetic Kidney Disease Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Kidney Disease Market.

The Diabetic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Diabetic Kidney Disease Pipeline Report: https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Diabetic Kidney Disease treatment therapies with a considerable amount of success over the years.
• Diabetic Kidney Disease companies working in the treatment market are Orbsen Therapeutics, Dimerix Bioscience, Inversago Pharma, CSL Behring, Kyowa kirin, and others, are developing therapies for the Diabetic Kidney Disease treatment
• Emerging Diabetic Kidney Disease therapies in the different phases of clinical trials are- ORBCEL-M, DMX-200, INV-202, CSL346, Bardoxolone methyl, and others are expected to have a significant impact on the Diabetic Kidney Disease market in the coming years.
• In November 2024, At the American Heart Association (AHA) conference, during a key session titled "GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics," Dr. Katherine Tuttle explored the renal benefits of glucagon-like peptide-1 (GLP-1) receptor agonist therapy. She specifically highlighted Novo Nordisk's Ozempic (semaglutide), emphasizing its role in advancing GLP-1 treatments for managing diabetic kidney disease.
• In March 2024, Hua Medicine, based in China, intends to prioritize the development of its type 2 diabetes (T2D) medication for diabetic kidney patients in the United States. According to George Lin, the Chief Strategy Officer, the company aims to initiate clinical trials specifically tailored for the US market, focusing on creating a once-daily formulation of their drug Huatangning (dorzagliatin).

Diabetic Kidney Disease Overview
Diabetic kidney disease (DKD), also known as diabetic nephropathy, is a complication of diabetes characterized by damage to the kidneys' filtering units, known as nephrons. It is a common complication of both type 1 and type 2 diabetes. Over time, high levels of blood sugar can damage the blood vessels and filtration system in the kidneys, leading to impaired kidney function.

Get a Free Sample PDF Report to know more about Diabetic Kidney Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Diabetic Kidney Disease Drugs Under Different Phases of Clinical Development Include:
• ORBCEL-M: Orbsen Therapeutics
• DMX-200: Dimerix Bioscience
• INV-202: Inversago Pharma
• CSL346: CSL Behring
• Bardoxolone methyl: Kyowa kirin

Diabetic Kidney Disease Pipeline Therapeutics Assessment
• Diabetic Kidney Disease Assessment by Product Type
• Diabetic Kidney Disease By Stage and Product Type
• Diabetic Kidney Disease Assessment by Route of Administration
• Diabetic Kidney Disease By Stage and Route of Administration
• Diabetic Kidney Disease Assessment by Molecule Type
• Diabetic Kidney Disease by Stage and Molecule Type

DelveInsight's Diabetic Kidney Disease Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Diabetic Kidney Disease product details are provided in the report. Download the Diabetic Kidney Disease pipeline report to learn more about the emerging Diabetic Kidney Disease therapies at:
https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Diabetic Kidney Disease Therapeutics Market include:
Key companies developing therapies for Diabetic Kidney Disease are - AstraZeneca, Pfizer Inc., Novartis AG, Bayer AG, Sanofi Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Sun Pharmaceutical, and others.

Diabetic Kidney Disease Pipeline Analysis:
The Diabetic Kidney Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Kidney Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Kidney Disease Treatment.
• Diabetic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Diabetic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Kidney Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Diabetic Kidney Disease drugs and therapies-
https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diabetic Kidney Disease Pipeline Market Drivers
• Increasing prevalence of diabetes worldwide, rising geriatric population, increasing demand of novel therapies are some of the important factors that are fueling the Diabetic Kidney Disease Market.

Diabetic Kidney Disease Pipeline Market Barriers
• However, lack of skilled professionals to treat diabetic kidney disease in less developed countries, stringent regulatory guidelines and other factors are creating obstacles in the Diabetic Kidney Disease Market growth.

Scope of Diabetic Kidney Disease Pipeline Drug Insight
• Coverage: Global
• Key Diabetic Kidney Disease Companies: Orbsen Therapeutics, Dimerix Bioscience, Inversago Pharma, CSL Behring, Kyowa kirin, and others
• Key Diabetic Kidney Disease Therapies: ORBCEL-M, DMX-200, INV-202, CSL346, Bardoxolone methyl, and others
• Diabetic Kidney Disease Therapeutic Assessment: Diabetic Kidney Disease current marketed and Diabetic Kidney Disease emerging therapies
• Diabetic Kidney Disease Market Dynamics: Diabetic Kidney Disease market drivers and Diabetic Kidney Disease market barriers

Request for Sample PDF Report for Diabetic Kidney Disease Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Diabetic Kidney Disease Report Introduction
2. Diabetic Kidney Disease Executive Summary
3. Diabetic Kidney Disease Overview
4. Diabetic Kidney Disease- Analytical Perspective In-depth Commercial Assessment
5. Diabetic Kidney Disease Pipeline Therapeutics
6. Diabetic Kidney Disease Late Stage Products (Phase II/III)
7. Diabetic Kidney Disease Mid Stage Products (Phase II)
8. Diabetic Kidney Disease Early Stage Products (Phase I)
9. Diabetic Kidney Disease Preclinical Stage Products
10. Diabetic Kidney Disease Therapeutics Assessment
11. Diabetic Kidney Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Diabetic Kidney Disease Key Companies
14. Diabetic Kidney Disease Key Products
15. Diabetic Kidney Disease Unmet Needs
16 . Diabetic Kidney Disease Market Drivers and Barriers
17. Diabetic Kidney Disease Future Perspectives and Conclusion
18. Diabetic Kidney Disease Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Diabetic Kidney Disease Market
https://www.delveinsight.com/report-store/diabetic-kidney-disease-dkd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Diabetic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Diabetic Kidney Disease Epidemiology
https://www.delveinsight.com/report-store/diabetic-kidney-disease-dkd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Diabetic Kidney Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Transcatheter Heart Valve Replacement Devices Market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
• Bone Neoplasms Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Peak Flow Meters Market: https://www.delveinsight.com/report-store/peak-flow-meters-market
• Neuroendoscopy Market: https://www.delveinsight.com/report-store/neuroendoscopy-market
• Nosocomial Infections Market: https://www.delveinsight.com/report-store/nosocomial-infections-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Diabetic Kidney Disease Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment By DelveInsight | Orbsen Therapeutics, Dimerix Bioscience, Inversago Pharma, CSL Behring, Kyowa kirin here

News-ID: 3922502 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Diabetic

Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring
Leading Element Driving Change in the Diabetic Footwear Market in 2025: Rising D …
Which drivers are expected to have the greatest impact on the over the diabetic footwear market's growth? The surge in people with diabetes will spur the expansion of the diabetic footwear market in the future. Diabetes, characterised by high blood sugar levels, is a long-term health issue. Diabetic footwear can prevent severe foot-related issues caused by diabetes and offer several advantages such as enhanced blood flow, ample space for the toes,
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report. On the basis of
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025. To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282 Global Diabetic Socks Market: Factors Impacting the Market The primary factors driving the growth of the global diabetic socks market are increasing
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be